|
注册号: Registration number: |
ChiCTR2200063442 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-09 10:23:50 |
|
注册时间: Date of Registration: |
2022-09-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
淋巴瘤及多发性骨髓瘤患者治疗期间及治疗后心功能及心电学改变的前瞻性、观察性研究 |
|
Public title: |
A prospective and observational clinical trial of the change of cardiac function and electrocardiology in lymphoma and multiple myeloma patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
淋巴瘤及多发性骨髓瘤患者治疗期间及治疗后心功能及心电学改变的前瞻性、观察性研究 |
|
Scientific title: |
A prospective and observational clinical trial of the change of cardiac function and electrocardiology in lymphoma and multiple myeloma patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张威 |
研究负责人: |
刘海生 |
|
Applicant: |
Zhang wei |
Study leader: |
Liu haisheng |
|
申请注册联系人电话: Applicant telephone: |
+86 18830158009 |
研究负责人电话:
Study leader's |
+86 13933078299 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zw3200057831@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liuhs78299@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
河北医科大学第四医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
河北省石家庄市东开发区天山大街169号 |
研究负责人通讯地址: |
河北省石家庄市东开发区天山大街169号 |
|
Applicant address: |
169 Tianshan Street, East Development Zone, Shijiazhuang, Hebei, China |
Study leader's address: |
169 Tianshan Street, East Development Zone, Shijiazhuang, Hebei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河北医科大学第四医院 |
||
|
Applicant's institution: |
The Forth Hospital of Hebei Medical University |
||
|
研究负责人所在单位: |
河北医科大学第四医院 |
||
|
Affiliation of the Leader: |
The Forth Hospital of Hebei Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022KS011 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河北医科大学第四医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of the Forth Hospital of Hebei Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-04-19 00:00:00 | ||
|
伦理委员会联系人: |
张俊敏 |
||
|
Contact Name of the ethic committee: |
Junmin Zhang |
||
|
伦理委员会联系地址: |
河北省石家庄市健康路12号 |
||
|
Contact Address of the ethic committee: |
12 JianKang Road, Chang'an District, Shijiazhuang, Hebei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
河北医科大学第四医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Forth Hospital of Hebei Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省石家庄市东开发区天山大街169号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
169 Tianshan Street, East Development Zone, Shijiazhuang, Hebei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
NA |
||||||||||||||||||||||
|
研究疾病: |
淋巴瘤、多发性骨髓瘤 |
||||||||||||||||||||||
|
Target disease: |
lymphoma and multiple myeloma |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1.主要目的:观察淋巴瘤和多发性骨髓瘤患者治疗期间及治疗后心功能及心电学指标的变化。 2.次要目的:寻找可以早期预警心功能损害的超声及心电学指标。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Main objective: to observe the changes of cardiac function and electrocardiological indicators in patients with lymphoma and multiple myeloma during treatment and after treatment. 2. Secondary purpose: to find ultrasound and electrocardiological indicators that can warn of cardiac function damage in an early manner. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、年龄<18岁; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Aged < 18 years; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-09-01 00:00:00至 To 2023-09-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-01 00:00:00 至 To 2023-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
NA |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NA |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
NA |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
NA |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |